Assessment of Systemic Inflammation and Nutritional Indicators in Predicting Recurrence-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors

Lu, Zhenhua; Li, Rui; Cao, Xianglong; Liu, Chengyu; Sun, Zhen; Shi, Xiaolei; Shao, Weiwei; Zheng, Yangyang; Song, Jianguo

doi:10.3389/fonc.2021.710191

Cited by 4 publications

(2 citation statements)

References 57 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, Elif Yuce et al [ 43 ] found that PNI was not a risk factor for the prognosis of GIST patients. Furthermore, As Dolan et al [ 44 ] published a retrospective analysis including 160 patients who underwent GIST surgery, the authors demonstrated that SII could be used as a prognostic predictor. Similar results were obtained in another retrospective analysis that included 45 GIST patients [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib

Ding

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

Background Previous studies have confirmed that preoperative nutritional-inflammatory indicators can predict prognosis in various malignancies. However, to the best of our knowledge, no study has investigated the assessment of systemic inflammatory immunity index (SII) combined with prognostic nutritional index (PNI) scores to predict prognosis after neoadjuvant treatment with imatinib in locally advanced gastrointestinal stromal tumours (LA-GIST). The aim of this study was to evaluate the predictive value of pretreatment SII-PNI scores in predicting recurrence after neoadjuvant therapy with imatinib in patients with LA-GIST. Methods We retrospectively analyzed 57 patients with LA-GIST who received imatinib neoadjuvant from January 2013 to March 2019. Patients were divided into recurrence and non-recurrence groups according to their follow-up status, and SII and PNI cut-offs were calculated by receiver operating characteristic. The SII-PNI score ranged from 0 to 2 and were categorized into the following: score of 2, high SII (≥ 544.6) and low PNI (≤ 47.2); score of 1, either high SII (≥ 544.6) or low PNI (≤ 47.2); score of 0, no high SII (≥ 544.6) nor low PNI (≤ 47.2). Results All patients received imatinib neoadjuvant therapy for a median treatment period of 8.5 months (ranging from 3.2 to 12.6 months), with 8 patients (14.04%) and 49 patients (85.96%) developing recurrence and non-recurrence, respectively. Patients with a high SII-PNI score had a significantly worse recurrence-free survival time than those with a low SII-PNI score (P = 0.022, 0.046), and had a poorer pathological response (P = 0.014). Multivariate analysis demonstrated that the SII-PNI score was an independent prognostic factor for prediction of recurrence-free survival (P = 0.002). Conclusion The pre-treatment SII-PNI score can be used to predict the efficacy after neoadjuvant treatment with imatinib in patients with LA-GIST, which may be a promising predictor of recurrence-free survival time for patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib

Ding

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

show abstract

“…SII is calculated by multiplying platelet and NLR and also increases in cases of increased in ammation 21 . Various studies in the literature propose that SII may be used to determine prognosis in patients with malignant disease [22][23][24] .…”

Section: Discussionmentioning

confidence: 99%

Malign Tiroid Nodülleri için Biyolojik Belirteçlerin Prediktif Değeri. Tek Merkez Deneyimi

Çapoğlu

Bayhan

Gönüllü

et al. 2022

Journal of Biotechnology and Strategic Health Research

View full text Add to dashboard Cite

Background: Thyroid nodules are mostly benign. Although it varies by region, 5.4% of nodules in men and 6.5% of nodules in women may be malignant. In rural regions where a radiologist, an endocrine surgeon, a cytologist, and an endocrinologist are not present, difficulties may be experienced in the management of thyroid nodules. Objectives: This present study aims to determine if it is possible to comment on whether the nodule is malignant by evaluating the biological markers in patients with thyroid nodules. Methods: We reviewed retrospectively the data of patients between January 2019 and September 2020 who underwent total thyroidectomy in terms of thyroid ultrasonography results, thyroid fine-needle aspiration biopsy results, neutrophil, platelet, lymphocyte, red blood cell, and mean erythrocyte volume (MCV) values, histopathological examination results of thyroid specimens. Subsequently, we calculated Mentzer index, Systemic immune-inflammatory index, and neutrophil-lymphocyte ratio for each patient. Results: 140 patients were included in the study. 110 (78.6%) of the patients were female and 30 (21.4%) were male. The mean age of the patients was 48 ± 12.5 (20-76). There was no statistically significant difference in Mentzer index, Systemic inflammatory index, and neutrophil-lymphocyte ratios between patients with malignant and benign thyroid nodules. Conclusion: Biological markers have limited predictive power in the management of thyroid nodules. Therefore, the use of biomarkers that we have studied in the treatment of thyroid nodules does not seem possible at present.

show abstract

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Chen

Yang

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curative surgical resections and tyrosine kinase inhibitors (TKIs) are the main managements for localized GISTs and recurrent/metastatic GISTs, respectively. Despite multi-lines of TKIs treatments prolonged the survival time of recurrent/metastatic GISTs by delaying the relapse and metastasis of the tumor, drug resistance developed quickly and inevitably, and became the huge obstacle for stopping disease progression. Immunotherapy, which is typically represented by immune checkpoint inhibitors (ICIs), has achieved great success in several solid tumors by reactivating the host immune system, and been proposed as an alternative choice for GIST treatment. Substantial efforts have been devoted to the research of immunology and immunotherapy for GIST, and great achievements have been made. Generally, the intratumoral immune cell level and the immune-related gene expressions are influenced by metastasis status, anatomical locations, driver gene mutations of the tumor, and modulated by imatinib therapy. Systemic inflammatory biomarkers are regarded as prognostic indicators of GIST and closely associated with its clinicopathological features. The efficacy of immunotherapy strategies for GIST has been widely explored in pre-clinical cell and mouse models and clinical experiments in human, and some patients did benefit from ICIs. This review comprehensively summarizes the up-to-date advancements of immunology, immunotherapy and research models for GIST, and provides new insights and perspectives for future studies.

show abstract

Assessment of Systemic Inflammation and Nutritional Indicators in Predicting Recurrence-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors

Cited by 4 publications

References 57 publications

Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib

Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib

Malign Tiroid Nodülleri için Biyolojik Belirteçlerin Prediktif Değeri. Tek Merkez Deneyimi

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Contact Info

Product

Resources

About